Curiteva Surpasses More Than 10,000 Levels Successfully Treated

Jeffrey Mullin, MD, from University of Buffalo Neurosurgery shared his experience, stating “After using the Inspire Technology for the past two years in my high-risk patients, I’ve seen firsthand the rapid bone growth through and around the fusion construct, all without seeing any cases of pseudarthrosis or cage subsidence. This milestone is not only a celebration of the patients’ lives impacted but, it’s likely just the beginning of rapid market adoption given the exceptional outcomes when using the Inspire technology”.

Curiteva Receives FDA Nano Designation for Inspire 3D Printed Trabecular PEEK Technology

Eric Linder, Curiteva’s Co-Founder and Chief Technology Officer, highlighted the importance of this designation stating, “The FDA’s acknowledgment of our nanotechnology claim provides additional validation of our innovative design, confirming compliance with the agency’s guidelines for nanotechnology-based materials and reinforcing the Inspire technology as a pioneering solution within the medical implant sector.”

Curiteva Announces First Clinical Use of Inspire Standalone ALIF System

Dr. Randy Dryer, Curiteva’s CMO, was the first to implant the device. “Bringing the Inspire Standalone ALIF across the finish line and into the operating room is a significant accomplishment,” states Dr. Dryer following the procedure. “As we have seen with this technology, the visual verification of bone growth through the implant, paired with outstanding clinical results, aligns perfectly with what surgeons are seeking. I’m confident this implant will define a new standard for standalone ALIF procedures, delivering a best-in-class solution designed to enhance patient outcomes. I’m excited to incorporate this approach to my Inspire armamentarium.”

Curiteva Proudly Announces the Publication of a Peer-Reviewed Study in the Journal of Biomaterials

HUNTSVILLE, Ala., November 13, 2025 (Newswire.com) – Curiteva, Inc. a privately held manufacturing and technology company, proudly announces the publication of a peer-reviewed study, “Novel PEEK fabrication using fused strand deposition reduces inflammation and enhances MSC differentiation promoting bone growth and implant osseointegration,” in the Journal of Biomaterials (JBI). JBI is one of the most highly regarded and highest-impact journals in the biomaterials and materials science fields.

Curiteva Launches the Inspire Anterior Lumbar Portfolio

The Inspire portfolio builds upon its proven success, with more than 7,300 Inspire Interbodies already implanted across four product lines; Cervical, lumbar PLIF, lumbar TLIF and lumbar ALIF. Data underscores its efficacy, showcasing consistent evidence of both on-growth and through-growth throughout the implant’s structure, elevating the standard of patient care.

Curiteva(R) Secures FDA 510(k) Clearance for Inspire(R) Trabecular PEEK Standalone ALIF System

Dr. Stephen Tolhurst from Texas Back Institute noted, “I’ve been using the Inspire with HAFUSE technology for over two years. The results I am seeing and the timeframe in which they are achieved is striking. The implant design and cage technology are truly unique and allow for visual confirmation of bone growth both on and through the implant. I’m excited to bring the newly cleared Inspire Trabecular PEEK Standalone ALIF System into my practice and look forward to the positive impact it will have on patient outcomes.”

Curiteva & Promimic – Bonded by Innovation

HUNTSVILLE, Ala., May 6, 2025 (Newswire.com) – Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology, delivering advanced implant solutions with unmatched capabilities. The partnership combines Promimic’s groundbreaking surface modification with Curiteva’s innovative Inspire® technology, establishing a new benchmark in the medical device industry.

Curiteva Surpasses 5,000 Levels Treated with Its Novel Inspire Cervical 3D Printed Trabecular PEEK

HUNTSVILLE, Ala., April 15, 2025 (Newswire.com) – Curiteva, Inc., a pioneering technology and manufacturing company, is pleased to announce a significant achievement with over 5,000 levels successfully treated using the Inspire Cervical implant, just two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D printed trabecular PEEK implant, further establishing Curiteva’s presence as a leader in spine innovation.

Curiteva Surpasses 2,000 Procedures with Inspire®C Cervical Trabecular PEEK™ with HAFUSE® Technology

Huntsville, AL., (December 3, 2024) – Curiteva, Inc., a privately held manufacturing and technology company, today announced it has implanted over 2,000 patients with the Inspire®C Cervical Interbody Fusion Device. This success translates to more than 3,700 implants placed, demonstrating the system’s rapid adoption and effectiveness since its commercial launch in July 2023.

Unique Osseointegration Patterns in 3D Printed Trabecular-Architecture Porous Polyetheretherketone (PEEK). A CT Scan Study of the Inspire® Cervical Implant

Anterior cervical discectomy and fusion (ACDF) is a common procedure for the surgical treatment of degenerative pathologies of the cervical spine. The utilization of interbody fusion implants is a well-established technique to restore disk space height, alignment, decompress the exiting nerve roots, and provide surface area for fusion of the adjacent vertebrae. Successful fusion is critical for the long-term stability and function of the cervical spine and for maintenance of the overall clinical outcome. Polyetheretherketone (PEEK) is a material commonly used for interbody fusion implants. Benefits of PEEK include radiolucency, less stress shielding compared to titanium implants and improved modulus which may provide better loading characteristic. The ability to better visualize the fusion at the osseous-implant junction is a benefit preferred by many surgeons. Click here to read the full white paper.